UroGen Pharma Ltd. Q3 Loss decreases, beats estimates
Beam Global Posts Narrower Loss In Q3; Revenue Up 149%
Beam Global, (BEEM) posted a third quarter net loss of $3.6 million, compared to a loss of $6.8 million, a year ago. Loss per share was $0.26 compared to a loss of $0.67. On average, six analysts polled by Thomson Reuters expected the company to report a loss per share of $0.33, for the quarter. Analysts’ estimates typically exclude special items.
Third quarter revenue was $16.5 million, a 149% increase over prior year. Analysts on average had estimated $16.46 million in revenue.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
Natura &Co To Sell The Body Shop For 207 Mln Pounds To Aurelius
Natura &Co Holding S.A. (NTCO), a Brazilian global personal care cosmetics company, said on Tuesday that it has reached deal to sell its The Body Shop, a British cosmetics, skin care, and perfume brand, to private equity group, Aurelius, for 207 million pounds, including an earn-out of 90 million pounds.
The price and the earn-out will be payable in up to five years after closing of the transaction, expected to be closed by December 31.
Fabio Barbosa, CEO of Natura &Co, declared: “With the sale of The Body Shop, Natura &Co will now be able to fully concentrate on its core relationship selling expertise in Latin America while also continuing the optimization of Avon International’s footprint and investing in initiatives and innovations that positively impact people and the planet.”
U.S. Trade Deficit Widens More Than Expected In September
A report released by the Commerce Department on Monday showed the U.S. trade deficit widened by more than expected in the month of September.
The Commerce Department said the trade deficit increased to $61.5 billion in September from a revised $58.7 billion in August.
Economists had expected the trade deficit to climb to $60.2 billion from the $58.3 billion originally reported for the previous month.
The wider than expected deficit came as the value of imports surged by 2.7 percent to $322.7 billion in September after falling by 0.8 percent to $314.1 billion in August.
The spike in the value of imports partly reflected sharp increases in imports of cell phones and other household goods, passenger cars, capital goods and crude oil.
Meanwhile, the report said the value of exports shot up by 2.2 percent to $261.1 billion in September after jumping by 1.4 percent to $255.4 billion in August.
Exports of industrial supplies and materials and foods, feeds, and beverages saw notable growth during the month.
The Commerce Department also said the goods deficit widened to $86.3 billion in September from $84.6 billion in August, while the services surplus narrowed to $24.8 billion from $25.9 billion.
ISUN, INC. Q3 Loss decreases, but misses estimates
ISUN, INC. (ISUN) announced Loss for third quarter that decreased from last year but beat the Street estimates.
The company’s bottom line totaled -$2.2 million, or -$0.07 per share. This compares with -$4.9 million, or -$0.36 per share, in last year’s third quarter.
Analysts on average had expected the company to earn -$0.04 per share, according to figures compiled by Thomson Reuters. Analysts’ estimates typically exclude special items.
The company’s revenue for the quarter rose 46.8% to $27.9 million from $19.0 million last year.
ISUN, INC. earnings at a glance (GAAP) :
-Earnings (Q3): -$2.2 Mln. vs. -$4.9 Mln. last year.
-EPS (Q3): -$0.07 vs. -$0.36 last year.
-Analyst Estimates: -$0.04
-Revenue (Q3): $27.9 Mln vs. $19.0 Mln last year.
Full year revenue guidance: $95mln – $100mln
F9 Investments Proposes To Buy LL Flooring For $3/shr; Stock Up
F9 Investments, LLC or F9, said on Tuesday that it has sent an offer to LL Flooring Holdings, Inc. (LL), a retailer of hard-surface flooring, to acquire all shares of LL for $3 per share. F9, together with its affiliates, collectively owns around 8.8 percent of LL.
Following the news, LL was trading up by 4.61 percent at $2.95 per share in the pre-market trade on the New York Stock Exchange.
The proposed offer is fully financed through cash on hand and borrowing under an existing revolving credit facility from an affiliate of F9.
The value being offered by F9 reflects LL’s deteriorating financial performance, as disclosed in its third quarter results, as well as the Board’s refusal to meaningfully engage with F9 and its affiliates, following F9’s previously announced acquisition proposal.
F9’s owner, Thomas Sullivan said, “We believe our offer represents a compelling, immediate, and certain cash value for LL’s shareholders, in light of the company’s deteriorating financial condition and declining stock price, which in our view reflects the market’s lack of confidence in the current Board’s strategy.”
On May 26, F9 had presented the Board of LL with a cash offer of $5.76 per share. However, LL summarily rejected the proposal and F9 withdrew this offer following LL’s continued underperformance in the quarter ended June 30.
UroGen Pharma Ltd. Q3 Loss decreases, beats estimates
UroGen Pharma Ltd. (URGN) revealed Loss for third quarter that decreased from last year and missed the Street estimates.
The company’s bottom line came in at -$21.879 million, or -$0.68 per share. This compares with -$25.831 million, or -$1.13 per share, in last year’s third quarter.
Analysts on average had expected the company to earn -$0.85 per share, according to figures compiled by Thomson Reuters. Analysts’ estimates typically exclude special items.
The company’s revenue for the quarter rose 29.5% to $20.852 million from $16.097 million last year.
UroGen Pharma Ltd. earnings at a glance (GAAP) :
-Earnings (Q3): -$21.879 Mln. vs. -$25.831 Mln. last year.
-EPS (Q3): -$0.68 vs. -$1.13 last year.
-Analyst Estimates: -$0.85
-Revenue (Q3): $20.852 Mln vs. $16.097 Mln last year.